StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$84.78+10.38 (+13.95%)

Close on Nov 16, 2026Market cap $7.51BP/E –Yield –

CG Oncology operating margin

Operating margin is operating income as a percentage of revenue.

CG Oncology's operating margin for the twelve months ending Sep 30, 2026 was -4293.5%. For fiscal 2025 it was -4722.1%, against -10067.3% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-4722.1%+5345.1
FY2024Dec 31, 2024-10067.3%+17113.6
FY2023Dec 31, 2023-27180.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-3943.2%−874.2
Q2 FY2026Jun 30, 2026-7467.7%+73693.9
Q1 FY2026Mar 31, 2026-6130.1%+2214.0
Q4 FY2025Dec 31, 2025-2097.3%+63705.0
Q3 FY2025Sep 30, 2025-3069.0%+20222.0
Q1 FY2025Mar 31, 2025-81161.5%−76914.1
Q4 FY2024Dec 31, 2024-8344.1%+1927155.9
Q3 FY2024Sep 30, 2024-65802.3%+90231.0
Q2 FY2024Jun 30, 2024-23291.0%−18280.2
Q1 FY2024Mar 31, 2024-4247.4%–
Q4 FY2023Dec 31, 2023-1935500.0%–
Q3 FY2023Sep 30, 2023-156033.3%–
Q1 FY2023Mar 31, 2023-5010.8%–

More CG Oncology figures

See a number that looks wrong?